Type 2 diabetes mellitus has become one of the fastest growing public health problems worldwide. The disease is believed to involve a complex process involving genetic susceptibility and environmental factors. The human intestine harbors hundreds of trillions of bacteria, as well as bacteriophage particles, viruses, fungi, and archaea, which constitute a complex and dynamic ecosystem referred to as the gut microbiota. Increasing evidence has indicated changes in the gut microbiota composition or function in type 2 diabetic patients. An analysis of 'dysbiosis' enables the detection of alterations in the specific bacteria, clusters of bacteria, or bacterial functions associated with the occurrence of type 2 diabetes. These bacteria are involved predominantly in the control of inflammation and energy homeostasis. This review attempts to show that the gut microbiota are important factors for the occurrence of type 2 diabetes and are important for the treatment of gut microbiota dysbiosis through bariatric surgery, fecal microbiota transplantation, prebiotics, and probiotics. (Korean J Gastroenterol 2019;74:314-320) 
INTRODUCTION
Diabetes mellitus (DM) is a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia, resulting from deficiencies in insulin secretion, insulin action, or both. 1 Type 2 DM (T2DM), which accounts for ∼90-95% of diabetes cases, includes individuals with insulin resistance (IR) and frequently have relative insulin deficiency. 1, 2 Type 1 diabetes, which accounts for 10% of all cases, is characterized by an absolute deficiency of insulin secretion caused by pancreatic β-cell destruction, usually resulting from autoimmune attack. 3 The prevalence of T2DM is increasing rapidly, presumably because of the increasing incidence of obesity, reduced physical activity levels as countries become more industrialized, and aging of the population. 4 According to International Diabetes Federation, DM Atlas 2015 report, more than 75% of people with DM live in low and middle income countries. 5 In Africa, DM is expected to have the highest prevalence in the future, and the regional prevalence of DM has been reported to be 3.8% and is expected to increase to 4.3% in 2030. 6 The risk factors for DM include older age, obesity, family history of DM, prior history of gestational DM, impaired glucose tolerance, physical inactivity, and race/ethnicity. 7 The human gut microbiota is a complex ecosystem, which is a key component in the gastrointestinal tract (GIT) homeostasis. The involvement of the gut microbiota in immune diseases has recently been demonstrated, and a bacterial imbalance (dysbiosis) has been associated with pathologies, such as inflammatory bowel disease and obesity. [8] [9] [10] The gut microbiota is now considered a separate organ that is involved in regulating several physiological pathways by influencing different functions of the host. 11 Among these regulatory actions, the effect of gut microbes on the energy metabolism and the driving force in the pathogenesis of metabolic diseases, particularly obesity, is an important factor.
Intestinal microbes have established a mutually beneficial link with their host by modulating the gut motility, intestinal barrier homeostasis to prevent potentially harmful bacteria from causing damage to the tissues, nutrient absorption, and fat distribution. [12] [13] [14] Evidence shows that gut microbiota play a critical role in the development of obesity and T2DM. [15] [16] [17] Studies have suggested that obese people with IR can be characterized by an altered composition of gut microbiota, predominantly an elevated Firmicutes/Bacteroidetes ratio compared to healthy people. 18, 19 T2DM patients showed an altered intestinal microbiota, which is characterized by a decrease in the Bacteroidetes/ Firmicutes ratio and some functional bacteria (e.g., Bifidobacteria)
with an increase in various opportunistic pathogens as well as some endotoxins-producing gram negative bacteria 20-22 that alter the host energy metabolism through a specific polysaccharide utilization loci mechanism. 22 Moreover, the accumulation of gut-derived bacterial inflammatory molecules (e.g., lipopolysaccharide [LPS], peptidoglycans and flagellin) in the intestine is thought to hasten the inflammation in T2DM. 23, 24 The human intestine harbors hundreds of trillions of bacteria, as well as bacteriophage particles, viruses, fungi and archaea, which constitute a complex and dynamic ecosystem with which an individual lives in symbiosis throughout lifetime. 25 Host genetics is believed to contribute to the profile of the gut microbiome, living conditions including dietary habits, exposure to xenobiotic (such as drugs, toxicants, and additives) or stresses (such as surgery and infections) modulate the gut microbiota, occasionally for a limited period of time due to the resilience of this ecosystem. 26 The gut microbiota characterizes an environmental factor of T2DM that was abandoned in the past because of the complexity of its analysis 27 and to a lack of understanding of the mechanisms underlying the interactions between gut microbes and host metabolism.
Therefore, microbiota is comprised of microorganisms that not only monitor the body homeostasis but are also the driving force in the pathogenesis of metabolic disease. This review summarizes the current knowledge concerning the role of gut microbiota in T2DM pathogenesis and its related complications and provides novel insights and reliable information on the gut microbiota as a therapeutic role and potential intervention strategy for the management of DM complications.
GUT MICROBIOTA ROLE IN DM PATHOGENESIS
Microorganisms in the GIT are referred to collectively as the gut microbiota. Qin et al. 28 reported that the gut microbiota mainly encompasses four main phyla: Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria. These are vital in the host metabolism and physiology regulation. Mika et al. 29 discussed the microbiota during early childhood, which include Actinobacteria predominantly of the genus Bifidobacterium, that dominate the gut microbiota of breastfed infants. Through time, the microbiota gains a variety of new strains influenced by changes in diet and by disease, finally beginning to resemble the adult composition. 29 In addition, Prakash et al. 30 indicated that physical exercise could also modulate the gut microbiota.
The GIT is the primary site of interaction between the host immune system and microorganisms, both symbiotic and pathogenic. 31 The gut microbiota act as a protective mediator during pathological conditions. The GI system represents one and protective and metabolic functions, such as breast feeding, genetic background, antibiotics, diet, lifestyle, bacteria in the amniotic fluid, and delivery procedure. 34 In addition to 43 and colorectal cancer. 44, 45 Sabatino et al. 46 reported that dysbiosis is associated with endotoxemia and chronic inflammation, with a disturbance of the intestinal barrier and the depletion of useful bacteria that lead to different complications.
The hosts and their microbiomes develop symbiotic relationships through interactive evolutionary processes that mutually benefit both. Xie et al. 47 reported that resident symbionts regulate the host metabolism in many ways, integrating physiological homeostasis, immune-inflammatory signaling, and energy compliance. Carbohydrates are the primary sources of energy for both the human host and their microbes.
The gut microbiome can also act as an endocrine organ that translates the nutritional cues to hormone-like signals to control host physiology and diseases. The gut microbiome also interacts with the inflammatory, cardiovascular system via metabolic signaling pathways, which can lead to chronic systemic inflammation that is supported by different scholars.
Brown et al., 48 Boulangé et al., 49 Kelly et al., 50 and Paras et al. 51 indicated that the gut microbiome has interactions with systemic diseases, including obesity, diabetes, hepatopathy, rheumatoid arthritis, cancer, and cardiovascular diseases.
PATHOPHYSIOLOGY OF THE GUT MICROBIOTA ON DIABETICS
Over the past decade, there has been an increasing focus on gut microbiota as an important factor in the development of inflammatory disease in both humans and animals. 52, 53 The GIT microbiome interrelates with the host nutrition, envi- Firmicutes. 54 The microbiome of the gut activates changes in the intestine tight junction proteins and alkaline phosphatase activity in the gut environment, which may increase the gut permeability and lead to the pathogenesis of IR. 13 Cani et al. 55 attempted to explain the mechanism of how the gut bacteria induces the inflammatory state of obesity via the activity of LPS, which is a component of gram-negative bacterial cell walls that can activate the inflammatory process by binding to the CD14 toll-like receptor-4 (TLR-4) complex at the surface of innate immune cells. LPS is a ligand of TLR-4. 55 The importance of the TLR-4 pathways in metabolic disease was confirmed by the finding that a deletion of TLR-4
prevented high-fat diet-induced IR. 56 The Bacteroidetes/ Firmicutes ratio is an environmental factor that provides genetic material for an increased capacity to harvest energy from the diet. 57 Murphy et al. 58 reported that the higher en- which may lead to obesity and ultimately IR. 60 T2DM in humans was reported to be co-related to a lower abundance of butyrate-producing microbes and an increased abundance of Lactobacillus species. 22, 37 The intestinal bacteria generate short chain fatty acids (SCFAs) by fermenting dietary carbohydrates that humans can-not digest themselves. Martin et al. 61 reported that germ-free mice are devoid of SCFAs, indicating the importance of the gut microbiota for SCFA production in the intestine. The role of the GIT microbiome in the development of the metabolic syndrome that leads to DM pathogenesis has been described. 60 Microbial dysbiosis harms the intestinal wall integrity and allows the translocation of toxins from the gut lumen to the systemic circulation. This endotoxemia leads to low-grade inflammation, autoimmunity, and oxidative stress that may lead to beta cell destruction or IR. 60 
COMPLICATIONS OF THE GUT MICROBIOTA DYSBIOSIS ON T2DM
The harmful effects of hyperglycemia are separated into micro-vascular complications (diabetic nephropathy, neuropathy, and retinopathy) and macro-vascular complications (coronary artery disease, peripheral arterial disease, and stroke). 62 A disturbance in the composition of the microbiota is strongly related to the incidence of inflammatory diseases, supporting the key role of a commensal microbiota in host homeostasis. 63 Beli et al. 64 reported that intermittent fasting prevents diabetic retinopathy in mice by restructuring the microbiota towards species producing tauroursodeoxycholate and subsequent retinal protection by activating the Takeda G-protein-coupled receptor 5. Moreover, mice on an intermittent fasting regimen displayed significantly longer survival and a reduction in the diabetic retinopathy endpoints, including acellular capillaries and leukocyte infiltration. 64 Kanbay et al. 65 and Mafra and Fouque 66 reported that the gut microbiota interacts closely with the inflammatory, renal, cardiovascular, and endocrine systems via metabolic, humoral, and neural signaling pathways. They also indicated that favorable modification of the composition and function of the gut microbiome represents an alluring therapeutic target for the prevention and treatment of chronic kidney disease. 65, 66 For example, a disruption of the normal physiology of the microbiota in the gut causes DM complications. New insights into the role of the gut microbiota in DM complications could lead to the development of therapeutic strategies using probiotics to prevent and treat these metabolic disorders. 34 
GUT MICROBIOTA AS THERAPEUTIC ALTERNATIVES FOR DM
The gut microbial diversity, metalloproteins encoding gene expression in gut bacterial species, and glycemic index are improved during a metformin treatment for T2DM. 67 Recently, metformin has been proposed as an adjuvant treatment for cancer, 68 as a treatment for gestational diabetes, and for the prevention of T2DM in pre-diabetic individuals. 69 Stades et al. 70 suggested metformin, which is currently recommended by the practice guidelines as the first line therapy for the majority of patients with T2DM.
On the other hand, bariatric surgery alters the composition and diversity of the gut microbiota in humans, rats and mice significantly. [71] [72] [73] An alteration of microbial dysbiosis by supplementation with prebiotics improved bifidobacterium abundance, which is significantly and positively associated with improved glucose tolerance and inflammation in prebiotic treated mice. 74 Buchwald et al. 75 reported that the clinical and laboratory manifestations of T2DM are improved in a majority of patients after bariatric surgery. Strategies for the treatment of gut microbiota dysbiosis through the supplementation or ingestion of live beneficial bacteria (probiotics) have been suggested. 76 The reintegration of intestinal microbiota by the mean of pre-or pro-biotic is a treatment alternative for T2DM patients. 77 Probiotics are live, natural microorganisms that are given orally to deliberate health benefits to the host. 78 The interest in managing the microbiota composition to increase the potentially beneficial aspects has increased. The prebiotic approach dictates that non-viable food components fermented specifically in the colon by native bacteria have a positive value, e.g., Bifidobacteria and Lactobacilli. 77, 79 Fecal microbiota transplantation (FMT) also increased the survival rate of irradiated animals, raised the peripheral white blood cell counts, and improved the GIT function and intestinal epithelial integrity in irradiated male and female mice.
Cui et al. 80 reported that the transplantation of fecal microbiota from healthy mice to irradiated mice upgraded the GIT function and epithelial integrity of the small intestines in a sex-dependent fashion to ameliorate radiation-induced toxicity. Bang et al., 81 who examined FMT for refractory and recurrent Clostridium difficile infection (CDI), reported that FMT is a safe, well-tolerated, and highly effective treatment for re- The Korean Journal of Gastroenterology fractory/recurrent CDIs. Moreover, the authors also expect that FMT will be used widely to treat refractory/recurrent CDI.
CONCLUSIONS AND RECOMMENDATIONS
Epidemiological studies indicated the association of the gut microbiota and T2DM. In many studies, an association between the disturbance of gut microbiota and an increased incidence rate of T2DM was indicated. The energy metabolism is of particular interest because it has been proposed to be a driving force in the pathogenesis of metabolic diseases, particularly obesity that in turn induces T2DM. On the other hand, the supplementation of prebiotics is an important mechanism for the rehabilitation of gut microbiota and for the harmony of body homeostasis.
In general, the early detection and screening of new onset T2DM patients for gut microbiota dysbiosis are recommended for the management of patients with T2DM. Understanding the mechanisms of the relationship between DM and the gut microbiota is important for improving long-term survival.
Future research should examine the development of novel preventive and therapeutic strategies for gut microbiota alterations among T2DM patients.
